Bank of New Hampshire Sells 336 Shares of Novo Nordisk A/S (NYSE:NVO)

Bank of New Hampshire cut its position in Novo Nordisk A/S (NYSE:NVO) by 2.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 14,444 shares of the company’s stock after selling 336 shares during the quarter. Bank of New Hampshire’s holdings in Novo Nordisk A/S were worth $1,242,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in NVO. Norman Fields Gottscho Capital Management LLC raised its stake in Novo Nordisk A/S by 45.3% in the 4th quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company’s stock valued at $5,482,000 after acquiring an additional 19,870 shares during the period. Doliver Advisors LP increased its stake in shares of Novo Nordisk A/S by 54.5% in the fourth quarter. Doliver Advisors LP now owns 16,225 shares of the company’s stock worth $1,396,000 after purchasing an additional 5,721 shares in the last quarter. CWA Asset Management Group LLC bought a new stake in shares of Novo Nordisk A/S in the fourth quarter valued at approximately $2,722,000. Versant Capital Management Inc purchased a new stake in shares of Novo Nordisk A/S during the 4th quarter valued at approximately $86,000. Finally, Confluence Investment Management LLC boosted its holdings in Novo Nordisk A/S by 2.2% in the 4th quarter. Confluence Investment Management LLC now owns 10,274 shares of the company’s stock worth $884,000 after buying an additional 220 shares during the period. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

Shares of NVO traded down $0.42 during trading hours on Tuesday, reaching $84.61. 1,486,932 shares of the company’s stock traded hands, compared to its average volume of 5,045,703. Novo Nordisk A/S has a 12 month low of $81.50 and a 12 month high of $148.15. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. The stock has a market cap of $379.69 billion, a PE ratio of 27.38, a price-to-earnings-growth ratio of 1.37 and a beta of 0.45. The firm’s 50 day simple moving average is $102.51 and its 200-day simple moving average is $120.68.

Analysts Set New Price Targets

NVO has been the topic of several recent research reports. Cantor Fitzgerald restated an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. BMO Capital Markets dropped their price objective on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, December 23rd. StockNews.com lowered Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Finally, Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $140.20.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.